文献速递浆细胞疾病

来那度胺联合皮下硼替佐米及地塞米松作为新诊断多发性骨髓瘤诱导治疗的2期研究

Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.
PubMed 文献 · Am J Hematol · 2022-02-18

两项平行2期研究纳入88例新诊断多发性骨髓瘤患者,接受4周期来那度胺、皮下硼替佐米和地塞米松诱导治疗。可评估患者总缓解率为93.5%,完全或非常好的部分缓解占48.1%。最常见毒性为周围神经病变(汇总68%,3-4级7%)。

要点

  • 4周期诱导后可评估患者总缓解率93.5%,完全或非常好的部分缓解48.1%。
  • 最常见毒性为周围神经病变,汇总发生率68%,其中3-4级占7%。
  • 蛋白质组学提示激肽释放酶-6、中期因子和巨噬细胞炎性蛋白1α可能与疗效或神经毒性相关,需进一步研究。

核心结论

  • 来那度胺联合皮下硼替佐米和地塞米松诱导方案在可评估患者中总缓解率达93.5%,完全或非常好的部分缓解占48.1%。
  • 蛋白质组学提示激肽释放酶-6、中期因子和巨噬细胞炎性蛋白1α可能为预测疗效或毒性的生物标志物,需进一步研究。

研究设计与样本

  • 由爱尔兰癌症试验组(CTI;NCT02219178)和丹娜法伯癌症研究院(DFCI;NCT02441686)开展的两项平行2期研究。
  • 共入组88例,治疗84例;中位年龄CTI研究64.7岁、DFCI研究60.0岁;II-III期疾病分别占59%和57%。
  • 患者接受4个21天周期的来那度胺、皮下硼替佐米和地塞米松诱导治疗,之后可再接受4周期该方案或进行自体干细胞移植。
  • 诱导/移植后接受来那度胺维持治疗,高危患者加用硼替佐米。
  • 主要终点为4周期诱导后的总缓解率。

主要发现

  • 可评估患者4周期后汇总总缓解率为93.5%,其中完全或非常好的部分缓解占48.1%(CTI研究:91.9%、59.5%;DFCI研究:95.0%、37.5%)。
  • 全治疗人群总缓解率为85.7%,完全或非常好的部分缓解占44.0%。
  • 患者接受来那度胺、皮下硼替佐米和地塞米松的中位周期数CTI研究为4、DFCI研究为8。
  • CTI研究中60%患者接受移植、31%继续接受该方案诱导;DFCI研究中33%接受移植、51%继续接受该方案诱导。
  • 最常见毒性为周围神经病变(汇总:68%,3-4级7%;CTI研究:57%,3-4级7%;DFCI研究:79%,3-4级7%)。

局限性

  • 原文在蛋白质组学结果处写明「需进一步研究」。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are limited prospective data on lenalidomide, subcutaneous bortezomib, and dexamethasone (RsqVd) in transplant-eligible/transplant-ineligible patients with newly diagnosed multiple myeloma. Reliable biomarkers for efficacy and toxicity are required to better tailor therapy. Two parallel studies were conducted by Cancer Trials Ireland (CTI; NCT02219178) and the Dana-Farber Cancer Institute (DFCI; NCT02441686). Patients received four 21-day cycles of RsqVd and could then receive either another 4 cycles of RsqVd or undergo autologous stem cell transplant. Postinduction/posttransplant, patients received lenalidomide maintenance, with bortezomib included for high-risk patients. The primary endpoint was overall response rate (ORR) after 4 cycles of RsqVd. Eighty-eight patients were enrolled and 84 treated across the two studies; median age was 64.7 (CTI study) and 60.0 years (DFCI study), and 59% and 57% had stage II-III disease. Pooled ORR after 4 cycles in evaluable patients was 93.5%, including 48.1% complete or very good partial responses (CTI study: 91.9%, 59.5%; DFCI study: 95.0%, 37.5%), and in the all-treated population was 85.7% (44.0%). Patients received a median of 4 (CTI study) and 8 (DFCI study) RsqVd cycles; 60% and 31% of patients (CTI study) and 33% and 51% of patients (DFCI study) underwent transplant or received further RsqVd induction, respectively. The most common toxicity was peripheral neuropathy (pooled: 68%, 7% grade 3-4; CTI study: 57%, 7%; DFCI study: 79%, 7%). Proteomics analyses indicated elevated kallikrein-6 in good versus poor responders, decreased midkine in good responders, and elevated macrophage inflammatory protein 1-alpha in patients who stopped treatment from neurotoxicity, suggesting predictive biomarkers warranting further investigation.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. O'Gorman P, Laubach JP, O'Dwyer ME, et al. Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. Am J Hematol. 2022. PMID: 35132679. doi:10.1002/ajh.26491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。